Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

407 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
High-density lipoproteins: a consensus statement from the National Lipid Association.
Toth PP, Barter PJ, Rosenson RS, Boden WE, Chapman MJ, Cuchel M, D'Agostino RB Sr, Davidson MH, Davidson WS, Heinecke JW, Karas RH, Kontush A, Krauss RM, Miller M, Rader DJ. Toth PP, et al. Among authors: boden we. J Clin Lipidol. 2013 Sep-Oct;7(5):484-525. doi: 10.1016/j.jacl.2013.08.001. Epub 2013 Aug 11. J Clin Lipidol. 2013. PMID: 24079290 Review.
The therapeutic role of niacin in dyslipidemia management.
Boden WE, Sidhu MS, Toth PP. Boden WE, et al. J Cardiovasc Pharmacol Ther. 2014 Mar;19(2):141-58. doi: 10.1177/1074248413514481. Epub 2013 Dec 20. J Cardiovasc Pharmacol Ther. 2014. PMID: 24363242 Review.
HDL hypothesis: where do we stand now?
Tariq SM, Sidhu MS, Toth PP, Boden WE. Tariq SM, et al. Among authors: boden we. Curr Atheroscler Rep. 2014 Apr;16(4):398. doi: 10.1007/s11883-014-0398-0. Curr Atheroscler Rep. 2014. PMID: 24619460 Review.
Is HPS2-THRIVE the death knell for niacin?
Toth PP, Murthy AM, Sidhu MS, Boden WE. Toth PP, et al. Among authors: boden we. J Clin Lipidol. 2015 May-Jun;9(3):343-50. doi: 10.1016/j.jacl.2015.01.008. Epub 2015 Jan 30. J Clin Lipidol. 2015. PMID: 26073392 Review.
Antianginal Therapy for Stable Ischemic Heart Disease: A Contemporary Review.
Padala SK, Lavelle MP, Sidhu MS, Cabral KP, Morrone D, Boden WE, Toth PP. Padala SK, et al. Among authors: boden we. J Cardiovasc Pharmacol Ther. 2017 Nov;22(6):499-510. doi: 10.1177/1074248417698224. Epub 2017 Mar 31. J Cardiovasc Pharmacol Ther. 2017. PMID: 28361599 Review.
Metabolic syndrome cluster does not provide incremental prognostic information in patients with stable cardiovascular disease: A post hoc analysis of the AIM-HIGH trial.
Lyubarova R, Robinson JG, Miller M, Simmons DL, Xu P, Abramson BL, Elam MB, Brown TM, McBride R, Fleg JL, Desvigne-Nickens P, Ayenew W, Boden WE; Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes (AIM-HIGH) Investigators. Lyubarova R, et al. Among authors: boden we. J Clin Lipidol. 2017 Sep-Oct;11(5):1201-1211. doi: 10.1016/j.jacl.2017.06.017. Epub 2017 Jul 5. J Clin Lipidol. 2017. PMID: 28807460 Free PMC article. Clinical Trial.
Relations of GlycA and lipoprotein particle subspecies with cardiovascular events and mortality: A post hoc analysis of the AIM-HIGH trial.
Otvos JD, Guyton JR, Connelly MA, Akapame S, Bittner V, Kopecky SL, Lacy M, Marcovina SM, Muhlestein JB, Boden WE. Otvos JD, et al. Among authors: boden we. J Clin Lipidol. 2018 Mar-Apr;12(2):348-355.e2. doi: 10.1016/j.jacl.2018.01.002. Epub 2018 Jan 12. J Clin Lipidol. 2018. PMID: 29409728 Free PMC article. Clinical Trial.
Cardiovascular outcomes during extended follow-up of the AIM-HIGH trial cohort.
Probstfield JL, Boden WE, Anderson T, Branch K, Kashyap M, Fleg JL, Desvigne-Nickens P, McBride R, McGovern M; AIM-HIGH Investigators. Probstfield JL, et al. Among authors: boden we. J Clin Lipidol. 2018 Nov-Dec;12(6):1413-1419. doi: 10.1016/j.jacl.2018.07.007. Epub 2018 Jul 25. J Clin Lipidol. 2018. PMID: 30131256
407 results